There has been a lot of fuss recently about the corona vaccine from pharmaceutical company AstraZeneca.

After the European regulator EMA concluded that the vaccine is linked to very rare thrombosis, the Netherlands decided to stop administering AstraZeneca to people under the age of 60.

What have the other countries decided?

In short: what's going on around the AstraZeneca vaccine?

  • From all over Europe there were reports of - mostly women under the age of 60 - who developed thrombosis and a reduction in the number of blood platelets after vaccination.

  • This is a 'very rare' side effect, concluded the European Medicines Agency (EMA).

  • According to the EMA, the benefit of the vaccine still outweighs the risks it entails and the vaccine can be used as usual.

  • The Dutch Health Council was a bit more cautious and recommended that only people over 60 be injected with the AstraZeneca vaccine.

    For them, the benefits of the vaccination are worth the small risk, they argued.

France: People over 55 receive AstraZeneca, doubt about second dose

In mid-March, vaccination with AstraZeneca was temporarily halted in France, as in other European countries.

A few days after the stop, the French health authorities already advised that vaccination could be resumed, but only for people 55 and older.

As a result of last week's developments, doubts have arisen in France around the vaccination of people up to the age of 55 who have already had one dose of AstraZeneca.

When asked whether these more than 500,000 people should receive a second dose of the same vaccine, the French health council responded in the negative on Friday.

Their second dose should be a dose of the Moderna or Pfizer vaccine, the authority concluded.

Although the government has not yet definitively adopted this measure, it is expected that it will.

Germany: Mainly only over 60s, but exceptions possible

Only Germans over sixty should be given the AstraZeneca vaccine, the German government decided late last month.

However, the limit is not very strict, because doctors are still allowed to administer the vaccine to this patient at the request of a well-informed sixty-minute.

Discussion has also arisen in Germany about the second dose of AstraZeneca for people under the age of sixty.

Instead of a second dose of AstraZeneca, these people will receive a different MNRA vaccine, such as that from Moderna or Pfizer.

Not only Germany and the Netherlands have limited the injection of AstraZeneca to people over 60.

This age limit also applies in Spain, Portugal and Italy, among others.


Dent in the image of AstraZeneca vaccine, how do countries want to solve this?

Belgium: Short vaccination stop for people under 55

Following the position of the EMA, the Belgian government has decided to introduce a temporary injection stop for people under the age of 55.

In the coming month, the drug will only be used by people over 55.

This will not have a huge effect on the vaccination campaign among the southern neighbors, Belgian Health Minister Frank Vandenbroucke emphasized in Belgian media, including



At the moment, mainly people over 65 and people from certain risk groups were vaccinated, not many of whom are younger than 55.

At the beginning of May, the southern neighbors will see whether the vaccination can be resumed in its entirety.

Great Britain: Alternative for people under thirty

In Britain, people under the age of 30 are offered an alternative vaccine instead of AstraZeneca.

In this age group, a corona infection is much less dangerous, making it better to avoid the risk of the very rare side effect altogether, according to the British Medicines Authority MHRA.

Denmark: Has stopped for five weeks, will make a new decision next week

On March 25, Denmark decided to curtail the AstraZeneca vaccination process pending further investigation.

The fact that the EMA found a link between the vaccine and the very rare side effect last week, according to the country, underlines that it has been a careful decision to temporarily stop vaccination pending the investigation.

Although the EMA has concluded that the harms of the vaccine continue to outweigh the benefits, Denmark also wants to await the conclusion of its own researchers.

The results of the survey of the Danish vaccinated population are expected to come next week, after which the country will decide whether to resume vaccination or not.

See also: AstraZeneca side effect or dying from corona: risk is almost the same for a young woman